| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 6705 | 2020 |
| Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national … B De Pauw, TJ Walsh, JP Donnelly, DA Stevens, JE Edwards, T Calandra, ... Clinical infectious diseases 46 (12), 1813-1821, 2008 | 5975 | 2008 |
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis R Herbrecht, DW Denning, TF Patterson, JE Bennett, RE Greene, ... New England Journal of Medicine 347 (6), 408-415, 2002 | 4068 | 2002 |
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America TJ Walsh, EJ Anaissie, DW Denning, R Herbrecht, DP Kontoyiannis, ... Clinical infectious diseases 46 (3), 327-360, 2008 | 3779 | 2008 |
| Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America TF Patterson, GR Thompson III, DW Denning, JA Fishman, S Hadley, ... Clinical infectious diseases 63 (4), e1-e60, 2016 | 3611 | 2016 |
| Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group … JP Donnelly, SC Chen, CA Kauffman, WJ Steinbach, JW Baddley, ... Clinical Infectious Diseases 71 (6), 1367-1376, 2020 | 2975 | 2020 |
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus S Ascioglu, JH Rex, B De Pauw, JE Bennett, J Bille, F Crokaert, ... Проблемы медицинской микологии 5 (1), 10-16, 2003 | 2963 | 2003 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2681 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 2124 | 2021 |
| Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) PG Pappas, BD Alexander, DR Andes, S Hadley, CA Kauffman, A Freifeld, ... Clinical Infectious Diseases 50 (8), 1101-1111, 2010 | 1783 | 2010 |
| Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection … DP Kontoyiannis, KA Marr, BJ Park, BD Alexander, EJ Anaissie, TJ Walsh, ... Clinical Infectious Diseases 50 (8), 1091-1100, 2010 | 1782 | 2010 |
| Practice guidelines for diseases caused by Aspergillus DA Stevens, VL Kan, MA Judson, VA Morrison, S Dummer, DW Denning, ... Clinical Infectious Diseases, 696-709, 2000 | 1178 | 2000 |
| Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled … JA Maertens, II Raad, KA Marr, TF Patterson, DP Kontoyiannis, ... The Lancet 387 (10020), 760-769, 2016 | 1117 | 2016 |
| Invasive aspergillosis disease spectrum, treatment practices, and outcomes TF Patterson, WR Kirkpatrick, M White, JW Hiemenz, JR Wingard, ... Medicine 79 (4), 250-260, 2000 | 1080 | 2000 |
| Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ... The Lancet Infectious Diseases 21 (6), e149-e162, 2021 | 997 | 2021 |
| ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19-final report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... N Engl J Med 383 (19), 1813-1826, 2020 | 992 | 2020 |
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial TJ Walsh, I Raad, TF Patterson, P Chandrasekar, GR Donowitz, R Graybill, ... Clinical infectious diseases 44 (1), 2-12, 2007 | 928 | 2007 |
| Development of a definition of postacute sequelae of SARS-CoV-2 infection T Thaweethai, SE Jolley, EW Karlson, EB Levitan, B Levy, GA McComsey, ... Jama 329 (22), 1934-1946, 2023 | 923 | 2023 |
| Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment MC Arendrup, TF Patterson The Journal of infectious diseases 216 (suppl_3), S445-S451, 2017 | 832 | 2017 |
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy J Maertens, I Raad, G Petrikkos, M Boogaerts, D Selleslag, FB Petersen, ... Clinical Infectious Diseases 39 (11), 1563-1571, 2004 | 820 | 2004 |
